Pluristem in academic partnership to test cell therapy

Israel-based Pluristem Therapeutics Inc has entered into a long-term collaboration with the Hadassah Medical Center in Jerusalem to assess the potential efficacy of a cell therapy for the treatment of complications arising from bone marrow transplantations.

Go to the profile of Victoria English
Dec 04, 2014
0
0

Israel-based Pluristem Therapeutics Inc has entered into a long-term collaboration with the Hadassah Medical Center in Jerusalem to assess the potential efficacy of a cell therapy for the treatment of complications arising from bone marrow transplantations.

The university’s medical center will use preclinical models to evaluate the potential of the company’s allogeneic cell therapy which is derived from full-term human placentas. The cells are expanded in bioreactor systems and grown in a fully automated operation. The cells are understood to release therapeutic proteins in response to inflammation, haematological disorders, radiation damage and ischaemia.

The product in question is intended for the treatment and prevention of haematological deficiencies and complications of bone marrow and umbilical cord blood transplantation. Called PLX-RAD, it is Pluristem’s second cell therapy product candidate. The company also has a clinical-stage cell therapy programme for the treatment of multiple cardiovascular and orthopaedic indications.

Pluristem announced the collaboration on 4 December 2014.

Copyright 2014 Evernow Publishing Ltd

Go to the profile of Victoria English

Victoria English

Editor, MedNous, a publication of Evernow Publishing Ltd

Co-founder and editor of Evernow Publishing Ltd. International journalist with previous full-time editorial positions at Informa Plc, Thomson Reuters, McGraw-Hill and Dow Jones Inc. Have worked as a correspondent covering finance in New York, Amsterdam, Brussels and London, and covering healthcare and the life sciences in London.

No comments yet.